Equillium, Inc.

Equillium is hoping that unmet medical need and long-term efficacy will persuade the US Food and Drug Administration to approve itolizumab for acute graft-versus-host disease (aGVHD) despite its Phase

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Novartis Debuts Two Deals While Johnson & Johnson had the day’s largest acquisition with the $2bn offer for antibody-drug conjugate specialist Ambrx, Inc. (Also see " J&J Makes Its Biggest

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu